Carlos Arteaga
Director, Simmons Comprehensive Cancer Center · University of Texas Southwestern Medical Center
Credentials: · · ·
History
PresentSimmons Comprehensive Cancer Center · University of Texas Southwestern Medical Center
- Present
Harold C. Simmons Comprehensive Cancer Center · University of Texas Southwestern Medical Center
- Present
Oncology Programs · University of Texas Southwestern Medical Center
1988–1990
Research
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
New England Journal of Medicine · 2016 · 1,581 citations
Molecular Biology of the Cell · 2001 · 870 citations
Journal of Biological Chemistry · 2000 · Last of 5 authors · 853 citations
41 papers
36 papers
34 papers
- LH
34 papers
34 papers
33 papers
- SH
33 papers
- AC
Alice Chen
23 papers
Grants
- 2010–2031
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
National Cancer Institute · P30
Contact PI · $36.8M · Ut Southwestern Medical Center
- 2023–2029
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancer
National Cancer Institute · R01
PI · $1.6M · Vanderbilt University Medical Center
- 2003–2024
National Cancer Institute · P50
Contact PI · $36M · Vanderbilt University Medical Center
- 2018–2024
Role of HER2 Mutations in Breast Cancer Progression and Response to Targeted Therapies
National Cancer Institute · R01
Contact PI · $1.8M · Ut Southwestern Medical Center
Clinical trials
- 2002–2007
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Study chair · Completed · Phase 2
Vanderbilt-Ingram Cancer Center
- 2024–2031
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Sub-investigator · Recruiting · Phase 2
Vanderbilt-Ingram Cancer Center